TARIS Biomedical Initiates Phase 2 Clinical Study with LiRIS® in Interstitial Cystitis Patients  
11/30/2011 9:08:22 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical, Inc., a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 2 clinical study with its novel product candidate, LiRIS®, in patients with Interstitial Cystitis. LiRIS® is designed to continuously deliver lidocaine over an extended period directly to the bladder to relieve symptoms associated with Interstitial Cystitis, such as bladder pain and voiding dysfunction.